SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir's recent report and forward guidance are sparking heated debate, with some celebrating the company's growth in the AI space while others express concerns about its high valuation. The community is divided between those who see long-term potential and those who anticipate a correction. Discussions also involve CEO Karp's commentary and Michael Burry's short position against the stock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid community discussion around a failed confirmatory trial for its PMO therapies, overshadowing otherwise positive earnings reports. Investors are weighing the implications of the trial results on future revenue, particularly in light of Elevidys sales and potential impacts on payer coverage.  Debate centers on whether the market reaction is an overcorrection and if long-term prospects remain strong due to potential buyouts or positive developments in the pipeline.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid mixed sentiment following earnings, with community discussions focusing on revenue beats versus EPS miss and potential risks related to debt and dilution. While some traders are securing profits, others see the dip as a buying opportunity, especially with ongoing developments in nuclear energy and rare earth elements. The stock's movement is also influenced by broader geopolitical factors affecting the rare earth sector.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amid discussions around Q3 earnings, potential short squeeze, and a possible partnership with Novo Nordisk. Community talking points revolve around the company's growth potential, expansion into new markets like comprehensive testing and international, and revenue acceleration, with some expressing concerns around profitability and volatility. Speculation around partnerships and target prices is also contributing to the heightened interest.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss its upcoming earnings report and the recent unveiling of a new e-bike. Community members are debating the company's long-term viability, R2 launch, build quality, service center experiences, potential partnerships, and overall strategy in a competitive EV market.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors discuss a potential offering following recent earnings and a new clinical program, while also considering the impact of a new CFO. The community debates management's spending and strategy, as well as the lawsuit against CMS, with some expressing frustration over the stock's performance despite company progress. Bullish investors focus on revenue growth, potential acquisitions, and positive analyst ratings, while bears cite concerns about dilution and management decisions.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant drop following the FDA's changed stance on clinical trial data for its Huntington's disease therapy, with the community debating the reasons and potential fallout; some speculate about regulatory setbacks and compare it to other biotech firms, while others see a buying opportunity amidst the volatility. The stock's movement is heavily discussed in the context of broader biotech industry trends and potential for future acquisitions.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Tidal Trust II - Defiance Daily Target 2x Short PLTR ETF

Defiance Daily Target 2x Short PLTR ETF

PLTZ is trending as traders anticipate a potential downturn for PLTR, with community members actively discussing shorting opportunities after recent earnings and amidst valuation concerns. Some traders are using PLTZ to bet against PLTR, citing its high P/E ratio and potential for a significant pullback, while others debate the timing and strategy for shorting the stock.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is experiencing a surge, with community members pointing to its low supply and comparing its potential to ZEC's previous moves. Some traders are noting DASH's undervaluation and increased trading volume, while others speculate about potential integrations and its role in the privacy coin sector. The community also highlights its strong performance amidst a sea of red, attracting day traders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

kelly linds

Bilvo

Theresa Fouad

Gambler71

Mike rasmussen

Brandon

Jeremy Smith

b.roke

Sammy Leonidas

SCOTT SUH

Barry Nzegwu

Steve call

COVID19 #Novavax SerumSerum Institute of India CEO Adar Poonawalla speaks with Yahoo Finance's Anjalee Khemlani about global vaccination efforts to combat C...